Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
5 hedge funds and large institutions have $298K invested in Therapix Biosciences Ltd. in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$215K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$96.1K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$8.79K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.07K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.02K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $198K | +$215K | +24,462 | New |
|
|
VKH
2
Virtu KCG Holdings
New York
| $88K | +$96.1K | +10,931 | New |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | +$8.79K | +1,000 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$2.02K | +230 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2K | +$2.07K | +235 | New |
|
TRPX Hedge Fund Activity: Q1 2017 in Review
5 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q1 2017, worth a combined $298K.
Buyers outnumbered sellers: 5 funds opened new TRPX positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $215K.
- 5 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q1 2017, up from 0 in Q4 2016.
- Funds reported $298K of Therapix Biosciences Ltd. stock for Q1 2017.
- 5 funds opened new Therapix Biosciences Ltd. positions in Q1 2017 and 0 closed out, a net change of +5 holders.
- The largest Therapix Biosciences Ltd. buyer in Q1 2017 was Morgan Stanley, an estimated $215K added.
Based on aggregated 13F filings for Q1 2017.